Preterm infants born younger than 29 weeks’ gestation who are treated for pulmonary hypoplasia with inhaled nitric oxide do not have an increased chance of in-hospital survival, according to findings published in JAMA Pediatrics.
“Because blood vessel growth in the lung parallels airway development, pulmonary hypoplasia is often complicated by persistent pulmonary hypertension of the newborn, or PPHN,” Kevin R. Ellsworth, MD, from the division of neonatal medicine at the Mayo Clinic, and colleagues wrote. “Pulmonary hypertension is a major contributor to physiologic compromise in these patients, including severe, refractory hypoxemic respiratory failure. To date, to our knowledge, no postnatal therapy has been shown to consistently increase survival in preterm neonates with pulmonary hypoplasia.”
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.